Nature Search

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

The regulation of resistance to IDH inhibitors in acute myeloid leukaemia is not completely understood. Here the authors reveal with integrative multi-omics analyses that stemness features are major drivers of primary resistance, while high-risk mutations drive acquired resistance.

Feng Wang
Kiyomi Morita
Koichi Takahashi
ResearchOpen Access10 May 2021
Nature Communications

Volume: 12, P: 1-13
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Mapping of the clonal structure of bone marrow cells in patients with acute myeloid leukemia treated with the IDH2 inhibitor enasidenib reveals heterogeneity in the cellular differentiation response and in mechanisms of relapse.

Lynn Quek
Muriel D. David
Paresh Vyas
Research16 Jul 2018
Nature Medicine

Volume: 24, P: 1167-1177
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

Ovarian tumors with common mutations in the epigenetic regulator ARID1A are shown to be sensitive to inhibition of EZH2, another epigenetic regulator, showing a synthetic lethality that could potentially be exploited therapeutically

Benjamin G Bitler
Katherine M Aird
Rugang Zhang
Research16 Feb 2015
Nature Medicine

Volume: 21, P: 231-238
A global database for metacommunity ecology, integrating species, traits, environment and space

Alienor Jeliazkov
Darko Mijatovic
Jonathan M. Chase
ResearchOpen Access08 Jan 2020
Scientific Data

Volume: 7, P: 1-15
Rate of CRL4^CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

C C Bjorklund
L Lu
A G Thakurta
ResearchOpen Access02 Oct 2015
Blood Cancer Journal

Volume: 5, P: e354
The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells

M R Russell
W L Jamieson
A Fatatis
Research13 Oct 2008
Oncogene

Volume: 28, P: 412-421

Quick links

Search

Filter By:

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

A global database for metacommunity ecology, integrating species, traits, environment and space

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

The α-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells

Search

Quick links

Rate of CRL4^CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4